Q-Symbio is the abbreviated name for the two-year multi-center, randomized, double-blind, placebo-controlled study of Coenzyme Q10 supplements as an adjunct treatment of chronic heart failure patients. The name reflects the focus of the study on the SYMptoms, BIomarker status (BNP), and long-term Outcomes (hospitalizations and mortality) of the supplementation.
The data from the Q-Symbio study show that long-term supplementation with 300 milligrams per day is safe, improves symptoms and survival, and reduces the risk of major adverse cardiovascular events.